$12.93
0.69% yesterday
Nasdaq, Sep 24, 10:16 pm CET
ISIN
US4834971032
Symbol
KALV

KalVista Pharmaceuticals, Inc. Stock price

$12.93
-0.06 0.46% 1M
+0.68 5.55% 6M
+4.46 52.66% YTD
+3.28 33.99% 1Y
-0.45 3.36% 3Y
+0.18 1.41% 5Y
-52.59 80.27% 10Y
-64.91 83.39% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.09 0.69%
ISIN
US4834971032
Symbol
KALV
Industry

Key metrics

Basic
Market capitalization
$653.3m
Enterprise Value
$594.1m
Net debt
positive
Cash
$191.5m
Shares outstanding
50.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
456.8 | 16.4
EV/Sales
415.5 | 14.9
EV/FCF
negative
P/B
16.0
Financial Health
Equity Ratio
38.0%
Return on Equity
-
ROCE
-59.2%
ROIC
-1,584.0%
Debt/Equity
3.2
Financials (TTM | estimate)
Revenue
$1.4m | $39.8m
EBITDA
$-103.9m | $-168.2m
EBIT
$-104.8m | $-182.4m
Net Income
$-102.4m | $-185.3m
Free Cash Flow
$-168.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
32.9% | -
EBIT
32.6% | -
Net Income
27.8% | -
Free Cash Flow
-63.2%
Margin (TTM | estimate)
Gross
58.6%
EBITDA
-7,282.7% | -422.4%
EBIT
-7,350.6%
Net
-7,178.4% | -465.2%
Free Cash Flow
-11,814.2%
More
EPS
$-1.9
FCF per Share
$-3.3
Short interest
23.6%
Employees
150
Rev per Employee
-
Show more

Is KalVista Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

KalVista Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a KalVista Pharmaceuticals, Inc. forecast:

Buy
94%
Hold
6%

Financial data from KalVista Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
1.43 1.43
-
100%
- Direct Costs 0.59 0.59
-
41%
0.84 0.84
-
59%
- Selling and Administrative Expenses 74 74
19% 19%
5,166%
- Research and Development Expense 32 32
66% 66%
2,222%
-104 -104
33% 33%
-7,262%
- Depreciation and Amortization 0.97 0.97
14% 14%
68%
EBIT (Operating Income) EBIT -105 -105
33% 33%
-7,330%
Net Profit -102 -102
28% 28%
-7,158%

In millions USD.

Don't miss a Thing! We will send you all news about KalVista Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

KalVista Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
about 7 hours ago
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities...
Neutral
Business Wire
about 14 hours ago
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuan...
Neutral
Business Wire
6 days ago
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved EKTERLY® (sebetralstat), a novel, oral plasma kallikrein inhibitor, for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents age...
More KalVista Pharmaceuticals, Inc. News

Company Profile

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

Head office United States
CEO Ben Palleiko
Employees 150
Founded 2004
Website www.kalvista.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today